Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 11,349 matching trials from the live ClinicalTrials.gov search.
Conditions
Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Interventions
ELA026
Drug
Lead sponsor
Electra Therapeutics Inc.
Industry
Eligibility
6 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 11 more
Conditions
Pancreatic Neoplasms, Cholestasis
Interventions
nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Scottsdale, Arizona • Detroit, Michigan
Conditions
Epilepsy
Interventions
Placebo, BIA 2-093 3000 mg once daily, BIA 2-093 3600 mg once daily
Drug
Lead sponsor
Bial - Portela C S.A.
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Miramar, Florida
Completed Not applicable Interventional Accepts healthy volunteers Results available

Optimizing tDCS to Improve Dual Task Gait and Balance

NCT04295798
Conditions
Aging
Interventions
Conventional tDCS, Optimized tDCS, Conventional Sham, Optimized Sham
Device
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
65 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Roslindale, Massachusetts
Conditions
Type 2 Diabetes, Overweight, Cardiovascular (CV) Risk
Interventions
Tirzepatide, Dulaglutide, Semaglutide, Sitagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
887,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Osteosarcoma
Interventions
Losartan, Sunitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia
Conditions
Advanced Solid Malignancies
Interventions
CT7001, Fulvestrant
Drug
Lead sponsor
Carrick Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
12
States / cities
Tucson, Arizona • Beverly Hills, California • Tampa, Florida + 9 more
Conditions
Human Immunodeficiency Virus
Interventions
TMB-607, Placebo
Drug
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Neuroendocrine Tumors
Interventions
18F-MFBG (meta-fluoro benzylguanidine), Positron emission tomography (PET) imaging, Blood draws
Radiation · Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
5 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
New York, New York
Recruiting Phase 2 Interventional

The CARDIOPROTECT Trial

NCT07654426
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions
Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Postoperative Cognitive Complications, Delirium, Perioperative/Postoperative Complications, Brain Injuries, Anesthesia
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Breast Cancer
Interventions
Neoadjuvant Olaparib monotherapy group, Neoadjuvant combination therapy with olaparib plus durvalumab
Drug · Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Loveland, Colorado • Boston, Massachusetts • Portland, Oregon + 1 more
Conditions
Thrombosis, Cancer, Pulmonary Embolism
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Boston, Massachusetts + 4 more
Conditions
Alcohol Associated Hepatitis
Interventions
INT-787, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Fresno, California • Palo Alto, California • Sacramento, California + 17 more
Completed No phase listed Observational Accepts healthy volunteers

Human Papillomavirus (HPV) Infection in Pregnancy

NCT00194311
Conditions
Papillomavirus Infections, Pregnancy Complications
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Recruiting No phase listed Observational

Duloxetine Metabolism and Fibromyalgia

NCT06866444
Conditions
Fibromyalgia, Duloxetine
Interventions
Observational
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Phase 1Phase 2 Interventional Results available

Amgen 386 for Recurrent Glioblastoma

NCT01290263
Conditions
Glioblastoma Multiforme
Interventions
Amgen 386, Bevacizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
6
States / cities
Los Angeles, California • Boston, Massachusetts • Worcester, Massachusetts + 2 more
Conditions
Multiple Myeloma
Interventions
P-BCMA-101 CAR-T cells, Rimiducid
Biological · Drug
Lead sponsor
Poseida Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Gilbert, Arizona • Davis, California • San Diego, California + 11 more
Conditions
Non-Hodgkins Lymphoma, Multiple Myeloma, B-All
Interventions
Acalabrutinib, ACP-319
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
7
States / cities
Orange, California • Bethesda, Maryland • Rochester, New York + 4 more
Conditions
Ornithine Transcarbamylase (OTC) Deficiency
Interventions
scAAV8OTC, Reactive Corticosteroid Taper Regimen, Prophylactic Corticosteroid Taper Regimen
Genetic · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
Conditions
Lung Cancer
Interventions
Cemiplimab, Kevzara (Sarilumab)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Completed No phase listed Observational Accepts healthy volunteers

Audio Data Collection for Identification and Classification of Coughing

NCT04326309
Conditions
COVID-19, Coronavirus Infections, Hay Fever, Asthma, Chronic Obstructive Pulmonary Disease, Influenza, Common Cold, Respiratory Tract Infections, Healthy
Interventions
Not listed
Lead sponsor
HealthMode Inc.
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Advanced Heart Failure, Mechanical Circulatory Support, Left Ventricular Assist Device, Palliative Care
Interventions
Palliative care intervention
Behavioral
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Fairfax, Virginia
Conditions
Pediatric Solid Organ Transplant
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
Up to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska